Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

Journal of Immunology

Volumn 176, Issue 1, 2006, Pages 284-290

  Bunt, Stephanie K ^a   Sinha, Pratima ^a   Clements, Virginia K ^a   Leips, Jeff ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; IMMUNOSURVEILLANCE; INFLAMMATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 29644442445     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.1.284     Document Type: Article

References (41)

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
2. Kuper, H., H. O. Adami, and D. Trichopoulos. 2000. Infections as a major preventable cause of human cancer. J. Intern. Med. 248: 171-183.
3. Shacter, E., and S. A. Weitzman. 2002. Chronic inflammation and cancer. Oncology 16: 217-226.
4. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
5. Kusmartsev, S., and D. I. Gabrilovich. 2002. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51: 293-298.
6. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
7. Vakkila, J., and M. T. Lotze. 2004. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4: 641-648.
8. Apte, R. N., and E. Voronov. 2002. Interleukin-1: a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 12: 277-290.
9. Song, X., E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Björkdahl, S. Segal, C. A. Dinarello, and R. N. Apte. 2003. Differential effects of IL-1α and IL-1β on tumorigenicity patterns and invasiveness. J. Immunol. 171: 6448-6456.
10. Saijo, Y., M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, and T. Nukiwa. 2002. Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J. Immunol. 169: 469-475.
11. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650.
12. Vidal-Vanaclocha, P., C. Amezaga, A. Asumendi, G. Kaplanski, and C. A. Dinarello. 1994. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 54: 2667-2672.
13. Anasagasti, M. J., E. Olaso, F. Calvo, L. Mendoza, J. J. Martin, J. Bidaurrazaga, and F. Vidal-Vanaclocha. 1997. Interleukin 1-dependent and -independent mouse melanoma metastases. J. Natl. Cancer Inst. 89: 645-651.
14. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493.
15. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
16. Miller, F. R., B. E. Miller, and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3: 22-31.
17. Bronte, V., P. Serafini, E. Apolloni, and P. Zanovello. 2001. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24: 431-446.
18. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678-689.
19. + myeloid cells. J. Immunol. 166: 5398-5406.
20. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/ CD28 costimulation. J. Immunol. 165: 779-785.
21. lo thymocytes in vivo. Science 250: 1720-1723.
22. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157: 978-983.
23. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
24. Ostrand-Rosenberg, S., M. J. Grusby, and V. K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165: 6015-6019.
25. + T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 64: 1867-1874.
26. Wingren, A. G., O. Björkdahl, T. Labuda, L. Björk, U. Andersson, U. Gullberg, G. Hedlund, H.-O. Sjögren, T. Kalland, B. Widegren, and M. Dohlsten. 1996. Fusion of a signal sequence to the interleukin-1β gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol. 169: 226-237.
27. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645.
28. Zar, J. H. 1999. Biostatistical Analysis. Prentice-Hall, Upper Saddle River, NJ.
29. Simms, E. L., and D. S. Burdick. 1988. Profile analysis of variance as a tool for analyzing correlated responses in experimental ecology. Diametrical Journal 30: 229-242.
30. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
31. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
32. Blaser, M. J., P. H. Chyou, and A. Nomura. 1995. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 55: 562-565.
33. Ernst, P. B., and B. D. Gold. 2000. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 54: 615-640.
34. Björkdahl, O., M. Dohlsten, and H.-O. Sjögren. 2000. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1β induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Gene Ther. 7: 1365-1374.
35. Björkdahl, O., A. G. Wingren, G. Hedhund, L. Ohlsson, and M. Dohlsten. 1997. Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo. Cancer Immunol Immunother. 44: 273-281.
36. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
37. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
38. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168: 689-695.
39. Huang, Q., J. Yang, Y. Lin, C. Walker, J. Cheng, Z. G. Liu, and B. Su. 2004. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat. Immunol. 5: 98-103.
40. Muroi, M., T. Ohnishi, and K. Tanamoto. 2002. Regions of the mouse CD14 molecule required for Toll-like receptor 2- and 4-mediated activation of NF-κB. J. Biol. Chem. 277: 42372-42379.
41. Danna, E. A., P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg. 2004. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64: 2205-2211.